# A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Source: https://onco.cc/trials/nct06785636/  
OnCo record `nct06785636` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Darolutamide in prostate cancer, run by Pathos AI, Inc., now recruiting.

## Summary

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC is a phase 1/2 interventional study registered as NCT06785636 by Pathos AI, Inc., with 120 participants planned, started 2025-02-07 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pocenbrodib, Pocenbrodib and Darolutamide. Conditions listed: mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06785636
- Phase: 1/2
- Setting: PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sponsor: Pathos AI, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06785636: https://clinicaltrials.gov/study/NCT06785636

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Darolutamide](https://onco.cc/drugs/darolutamide/)
- companies: [Pathos AI](https://onco.cc/companies/pathos-ai/)

---
JSON: https://onco.cc/api/v1/entities/nct06785636.json